THERAPEUTICS Roche RO5508887 BACE Inhibitor Small Molecule Amyloid-Related Three Phase 1 trials have been completed. In January 2012, a trial conducted in Strasbourg, France, concluded a test of RG7129 in 50 healthy men to assess safety and pharmacological parameters
THERAPEUTICS AstraZeneca Eli Lilly & Co. AZD3293 LY3314814 BACE inhibitor Small Molecule Amyloid-Related In December 2012, AstraZeneca started a Phase 1 study that evaluated the safety and pharmacological effects of single doses of oral AZD3293 in 72 healthy volun
THERAPEUTICS Biogen Eisai Co., Ltd. E2609 BACE inhibitor Small Molecule Amyloid-Related By March 2015, eight Phase 1 trials had been completed to evaluate the safety and pharmacology of elenbecestat in nearly 500 healthy volunteers and people with early Alzheimer'
Karolinska InstituteSweden